XORTX Therapeutics Revises Warrant Terms
Company Announcements

XORTX Therapeutics Revises Warrant Terms

Xortx Therapeutics (TSE:XRTX) has released an update.

XORTX Therapeutics Inc. has announced the amendment of exercise prices for over a million outstanding warrants to a uniform USD $5.00, following approval from the TSX Venture Exchange. In addition, a new warrant acceleration provision has been introduced, allowing the company to enforce exercise of the warrants if their common share price exceeds USD $6.50 for ten consecutive trading days. XORTX, a pharmaceutical company, focuses on the development of treatments for progressive kidney diseases and has several products in advanced stages of clinical development.

For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.

Looking for more investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!